950220.KQ announces 1-for-5 reverse split for 2026-06-10NeoImmuneTech, Inc.（950220.KQ）宣布 1:5 合股，生效日 2026-06-10

Corporate Action

950220.KQ (NeoImmuneTech, Inc.) implemented a 1-for-5 reverse stock split on June 10, 2026, a move formally disclosed via an 8-K filing with the U.S. Securities and Exchange Commission (SEC) on May 20, 2026. For market participants, this adjustment will alter total outstanding shares and per-share pricing, but does not directly alter the company’s underlying intrinsic value.

Mechanical Impact

This reverse split will reduce total outstanding shares by 80%: every five existing outstanding shares will be consolidated into one new share. Per-share trading prices will adjust proportionally by a factor of five to preserve the company’s total market capitalization. Total pre-split market value equals the product of original outstanding shares and original per-share price, while post-split value equals new outstanding shares multiplied by adjusted per-share price—these figures are identical, meaning the split itself creates no net real economic value.

Signal Interpretation

This 1-for-5 reverse split is most likely intended to meet the minimum share price listing requirements for the KOSDAQ market, while improving market perceptions of the stock’s pricing profile and addressing persistent low-share-price pressures. This type of split is common among clinical-stage biotech firms, and is typically undertaken to maintain listing eligibility rather than reflect improved operational performance.

What This Signal Does Not Prove

This reverse split alone does not confirm improved company fundamentals, accelerated clinical trial progress, or near-term revenue growth. Any such claims require additional official operational or financial disclosures to be validated.